The Relative Strength (RS) Rating for Harrow jumped into a new percentile Wednesday, as it got a lift from 63 to 72.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to the rest of the market.
Over 100 years of market history shows that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves. See if Harrow can continue to show renewed price strength and hit that benchmark.
Harrow has moved more than 5% past a 20.31 entry in a third-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% EPS growth in its most recent report. Revenue rose 38%.
The company holds the No. 149 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
